Dr. Craig Erickson has been conducting translational research in neurodevelopmental disorders for twenty years. He is the leader of a large translational medicine program at Cincinnati Children’s Hospital Medical Center built to enhance the ability to detect brain target engagement with treatment on an individual patient level. This has enabled Dr. Erickson to, from the earliest stages of human drug trials, detect potential meaningful, functional change in human subjects while additionally describing which specific patients may best respond to treatment. 

He holds several investigator-initiated INDs and is the inventor of several patents describing new treatment approaches in his fields of study. His work has been extensively supported by the National Institutes of Health, United States Centers for Disease Control, United States Department of Defense, stakeholder foundations, and biotechnology companies from around the world. Dr. Erickson is a Professor of Psychiatry at the University of Cincinnati College of Medicine-Affiliated and the Director of the Cincinnati Fragile X Research and Treatment Center.